Sanofi’s FDA Nod in Hemophilia Gives Patients More Convenience, Brings Roche New Competition
FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.
Information Courtesy By: Frank Vinluan, #HealthcareNews #Healthcare | Feeds
FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.
Click For More Details
2023-02-24 05:06
Except for the headline, this story has not been edited by Healthcare Central is published from a syndicated feed.